Get the Stockscreener App
4.19
1.18%
-0.05
After Hours:
4.19
Adc Therapeutics Sa stock is traded at $4.19, with a volume of 1.52M.
It is down -1.18% in the last 24 hours and up +7.16% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$4.24
Open:
$4.22
24h Volume:
1.52M
Relative Volume:
1.39
Market Cap:
$519.05M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-1.4203
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
+1.45%
1M Performance:
+7.16%
6M Performance:
+18.36%
1Y Performance:
+147.93%
1-Day Range:
$4.025
$4.22
1-Week Range:
$3.94
$4.41
52-Week Range:
$1.05
$4.80
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
4.19 | 525.24M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
ADC Therapeutics (ADCT) to Release Earnings on Tuesday - MarketBeat
ADC Therapeutics to Host Q4 2025 Financial Results Call - Intellectia AI
ADC Therapeutics (NYSE:ADCT) Sees Strong Trading VolumeHere's What Happened - MarketBeat
ADC Therapeutics delivers 70% return as Fair Value target hit - Investing.com
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ADCT: Pivotal data and new combinations position ZYNLONTA for major growth in lymphoma markets - TradingView
ADC Therapeutics sets March 10 call on 2025 results and operations - Stock Titan
ADCT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
ADC Therapeutics Announces Upcoming Investor Conference Schedule - Intellectia AI
ADC Therapeutics to Participate in March Investor Conferences - Finviz
ADC Therapeutics amends royalty deal with HealthCare Royalty - Investing.com India
ADC Therapeutics (NYSE:ADCT) Shares Up 6.7%Time to Buy? - MarketBeat
ADC Therapeutics Amends HealthCare Royalty Financing Agreement - marketscreener.com
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement - GuruFocus
ADC Therapeutics Amends Royalty Deal, Issues New Warrants - TipRanks
ADC Therapeutics amends royalty deal with HealthCare Royalty By Investing.com - Investing.com Canada
ADC Therapeutics grants warrants to Healthcare Royalty By Investing.com - Investing.com Canada
Stepan Co recently released a project impact forecast, estimating that the cash impact over the entire project cycle will range between $29 million and $44 million, while the non-cash impact is expected to be between $58 million and $62 million. - Bitget
ADC Therapeutics SA (ADCT) recently released its performance outlook, expecting the company to enter a substantial growth phase starting in 2027. - Bitget
Healthcare Royalty Partners granted warrants to purchase approximately 9.8 million ordinary shares to ADC Therapeutics SA. - Bitget
ADC Therapeutics SA announced that, in the event of a change of control, the acquirer will continue to pay royalties to the healthcare royalty company until the originally agreed cap amount is reached. - Bitget
ADC Therapeutics announces amended Healthcare Royalty Financing agreement - marketscreener.com
ADC Therapeutics grants warrants to Healthcare Royalty - Investing.com Australia
ADC Therapeutics Amends HCR Royalty Financing, Sets $150–$200 Million Change-of-Control Payment - TradingView
ADC Therapeutics (NYSE: ADCT) amends HCR royalty deal, adds warrants - Stock Titan
Analyst Calls: Is ADC Therapeutics SA affected by consumer sentimentWeekly Trade Recap & Daily Technical Stock Forecast Reports - baoquankhu1.vn
ADCT Should I Buy - Intellectia AI
Aug Patterns: Is CommScope Holding Company Inc stock undervalued right nowJuly 2025 Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
ADCT SEC FilingsAdc Therapeutics Sa 10-K, 10-Q, 8-K Forms - Stock Titan
ADC Therapeutics (ADCT) CMO granted 285,200-share RSU award, 24,603 withheld for taxes - Stock Titan
Redmile discloses 12.7% ADC Therapeutics (ADCT) ownership stake - Stock Titan
Has ADC Therapeutics (ADCT) outpaced other medical stocks this year? - MSN
ADC Therapeutics Announces Investigator-Initiated Study Abstract - GuruFocus
Will ADC Therapeutics SA stock sustain high P E ratiosMarket Activity Report & Risk Controlled Swing Trade Alerts - mfd.ru
What drives ADC Therapeutics SA’s stock priceJuly 2025 Setups & Growth Focused Investment Plans - mfd.ru
Can ADC Therapeutics SA stock deliver consistent earnings growth - mfd.ru
Can ADC Therapeutics SA deliver consistent dividends2025 Sector Review & Real-Time Volume Triggers - mfd.ru
Can ADC Therapeutics SA stock outperform in 2025 bull marketEarnings Miss & Safe Capital Growth Stock Tips - mfd.ru
Will ADC Therapeutics SA stock hit new highs in YEARQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - mfd.ru
Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $7.50 - Defense World
Bond Watch: Is ADC Therapeutics SA a stock for growth or value investorsGDP Growth & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5%Here's Why - MarketBeat
ADC Therapeutics (NYSE:ADCT) Trading Down 4.5%Here's What Happened - MarketBeat
ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5% – Here’s Why - Defense World
Little Excitement Around ADC Therapeutics SA's (NYSE:ADCT) Revenues - 富途牛牛
ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking - simplywall.st
Update On ADCs: Sales, Deals, Targets And Approvals - Citeline News & Insights
ADC Therapeutics Grants Stock Options to New Employees - Intellectia AI
ADC Therapeutics (ADCT) upgraded to buy: Here's why - MSN
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):